Acadia Pharmaceuticals | ACAD - 市值



金融业
股票价格
USD
资产
USD 1.61B
现金及等价物
USD 851.46M
销售成本
USD 24.79M
流动资产
USD 1.1B
流动负债
USD 305.52M
债务
USD 52.19M
EBIT
USD -4.62M
EBITDA
USD 20.32M
员工
653
EPS每股收益
USD 0.02
股本和储备
USD 1.25B
销售毛利
USD 243.27M
债务利息支出
USD 0
利息收入
USD 8.33M
贷款资金
USD 0
市值
USD 3.56B
净收入
USD 3.64M
营业费用
USD 272.68M
营业利润
USD -4.62M
普通股股本
USD 169.18M
PE价格收益
10.08
税前利润
USD 3.98M
销售收入
USD 268.06M
销售和管理费用
USD 160.79M
股票
USD 31.57M
贸易债权人
USD 12.25M
应收帐款人
USD 148.38M


市值 更改 日
Acadia Pharmaceuticals USD 3.8B 724M 2026-03
ALKERMES USD 5.88B 1.26B 2026-03
Alnylam Pharmaceuticals USD 44.15B 8.39B 2026-03
Biogen USD 26.9B 1.09B 2026-03
BioMarin Pharmaceutical USD 10.86B 553M 2026-03
Bristol-Myers Squibb USD 123.83B 14.02B 2026-03
Cara Therapeutics USD 366M 338M 2025-09
Corcept Therapeutics USD 4.32B 654M 2026-03
Cytokinetics USD 8.19B 420M 2026-03
Eisai JPY 1.42T 110.62B 2026-03
Eli Lilly USD 869.02B 146.97B 2026-03
Incyte USD 18.73B 660M 2026-03
J&J USD 579.15B 78.91B 2026-03
Moderna USD 20.15B 8.53B 2026-03
Neurocrine Biosciences USD 13.25B 890M 2026-03
Pfizer USD 153.81B 12.24B 2026-03
PTC Therapeutics USD 5.64B 460M 2026-03
Sarepta Therapeutics USD 2.28B 30M 2026-03
Ultragenyx Pharmaceutical USD 2.06B 159M 2026-03
Vanda Pharmaceuticals USD 279M 6M 2024-12
Vertex Pharmaceuticals USD 113.58B 1.44B 2026-03